SPATA7 Activators
SPATA7 activators engage in a variety of biochemical mechanisms to enhance its functional capacity within cells. Increased intracellular concentrations of cAMP are a common upstream event triggered by several of these activators. This elevation in cAMP is achieved through different means, including the direct stimulation of adenylate cyclase, inhibition of phosphodiesterases that degrade cAMP, and through the action of exotoxins that modify G-protein regulated adenylate cyclase activity. As a result, the activated protein kinase A (PKA) signaling pathway can potentially increase the transcription and activity of SPATA7. Additionally, some activators function by selectively inhibiting specific phosphodiesterase isoforms, thus preventing the breakdown of cAMP within particular cellular compartments, providing a sustained signal for SPATA7 activation through PKA-mediated pathways.
Moreover, the activation of SPATA7 is not limited to pathways involving PKA. Alternate cAMP-mediated signaling involving exchange proteins directly activated by cAMP (Epac) also plays a role. Epac activators contribute to SPATA7 activation by facilitating the action of downstream effectors such as Rap1, which leads to cellular responses that could logically include the upregulation of SPATA7 activity.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Acts as a beta-adrenergic agonist increasing cAMP levels, potentially promoting PKA activation which may lead to greater SPATA7 activity. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
A non-selective phosphodiesterase inhibitor that prevents cAMP degradation, possibly resulting in elevated SPATA7 activity through enhanced PKA signaling. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
A selective phosphodiesterase-4 inhibitor that prevents cAMP breakdown, potentially increasing SPATA7 activity by sustaining PKA activation. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $57.00 $159.00 $275.00 $678.00 | 37 | |
A prostaglandin that activates adenylate cyclase, potentially upregulating cAMP and thus could enhance SPATA7 activity via PKA signaling pathways. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
A phosphodiesterase-5 inhibitor that could prevent cAMP degradation, potentially resulting in enhanced SPATA7 activity by increasing PKA signaling. | ||||||
Anagrelide | 68475-42-3 | sc-491875 | 25 mg | $150.00 | ||
A phosphodiesterase-3 inhibitor that can increase cAMP accumulation, potentially resulting in increased SPATA7 activity through PKA pathway activation. | ||||||
Cilostamide (OPC 3689) | 68550-75-4 | sc-201180 sc-201180A | 5 mg 25 mg | $92.00 $357.00 | 16 | |
A selective phosphodiesterase-3 inhibitor that may prevent the breakdown of cAMP, potentially leading to an increase in SPATA7 activity via PKA signaling. | ||||||
Milrinone | 78415-72-2 | sc-201193 sc-201193A | 10 mg 50 mg | $165.00 $697.00 | 7 | |
Inhibits phosphodiesterase-3 and may result in increased intracellular cAMP levels, potentially enhancing SPATA7 activity through PKA-dependent pathways. | ||||||
Luteolin | 491-70-3 | sc-203119 sc-203119A sc-203119B sc-203119C sc-203119D | 5 mg 50 mg 500 mg 5 g 500 g | $27.00 $51.00 $101.00 $153.00 $1925.00 | 40 | |
A flavonoid that may activate PKA by increasing cAMP levels, potentially leading to higher SPATA7 activity. | ||||||